UIC
KNSA icon

Uniplan Investment Counsel’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Uniplan Investment Counsel’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-493
Closed -$23.7K – 201
2026
Q1 		$23.7K Buy
+493
New +$21.8K ﹤0.01% 171

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Uniplan Investment Counsel's KNSA Position: Q2 2026 in Review

Uniplan Investment Counsel sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 493 shares — an estimated $23.7K sold.

Uniplan Investment Counsel first reported a position in KNSA in Q1 2026 and held it in 1 quarter. The position peaked at $23.7K in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Uniplan Investment Counsel reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Uniplan Investment Counsel sold 493 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $23.7K.
  • Uniplan Investment Counsel first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Uniplan Investment Counsel's Kiniksa Pharmaceuticals position peaked at $23.7K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.